{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:02:09Z","timestamp":1793070129340,"version":"4.5.0"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"\n Importance<\/jats:title>\n The totality of the societal and individual impact of treatment-resistant depression (TRD) is unknown, as is the potential to prognosticate TRD. The generalizability of many observational studies on TRD is limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To estimate the burden of TRD in a large population-wide cohort in an area with universal health care by including data from both health care types (psychiatric and nonpsychiatric) and, further, to develop a prognostic model for clinical use.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study, a population-based observational study, assessed data from the Stockholm MDD Cohort for episodes of major depressive disorder (MDD) between 2010 and 2017 that fulfilled predefined criteria for TRD (\u22653 consecutive antidepressant treatments). Data analysis was performed from August 2020 to May 2022.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Outcomes were psychiatric and nonpsychiatric comorbid conditions, antidepressant treatments, health care resource utilization, lost workdays, all-cause mortality, and intentional self-harm and, in the prognostic model, TRD.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 158\u202f169 unipolar MDD episodes (in 145\u202f577 patients) were identified between January 1, 2012, and December 31, 2017 (64.7% women; median [IQR] age, 42 years [30-56]). Of these, 12\u202f793 episodes (11%) fulfilled criteria for TRD. The median (IQR) time from the start of MDD episode to TRD was 552 days (294-932). Selective serotonin reuptake inhibitor was the most common class of antidepressant treatment in all treatment steps, and 5907 patients (46.2%) received psychotherapy at some point before initiation of the third pharmacological antidepressant treatment. Compared with matched non-TRD episodes, TRD episodes had more inpatient bed-days (mean, 3.9 days; 95% CI, 3.6-4.1, vs 1.3 days; 95% CI, 1.2-1.4) and more lost workdays (mean, 132.3 days; 95% CI, 129.5-135.1, vs 58.7 days; 95% CI, 56.8-60.6) 12 months after the index date. Anxiety, stress, sleep disorder, and substance use disorder were all more common comorbid conditions in TRD episodes. Intentional self-harm was more than 4 times more common in TRD episodes. The all-cause mortality rate for patients with MDD with TRD episodes was 10.7\/1000 person-years at risk, compared with 8.7\/1000 person-years at risk for patients with MDD without TRD episodes (hazard ratio, 1.23; 95% CI, 1.07-1.41). Median time from start of the first antidepressant treatment to start of the second, and from start of the second antidepressant treatment to start of the third, was 165 and 197 days, respectively. The severity of MDD, defined using the self-rating Montgomery-\u00c5sberg Depression Rating Scale (MADRS-S) at time of MDD diagnosis, was found to be the most important prognostic factor for TRD (C index\u2009=\u20090.69).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, TRD was a common variant of MDD when including patients from both health care types, which is associated with a high disease burden for both patients and society. The median time between initiation of new antidepressant treatments was longer than recommended in current treatment guidelines, suggesting room for more structured and timely depression care.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2022.3860","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T11:01:18Z","timestamp":1671015678000},"page":"167","source":"Crossref","is-referenced-by-count":171,"title":["Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study"],"prefix":"10.1001","volume":"80","author":[{"given":"Johan","family":"Lundberg","sequence":"first","affiliation":[{"name":"Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"},{"name":"Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cars","sequence":"additional","affiliation":[{"name":"Sence Research, Uppsala, Sweden"},{"name":"Department of Medical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven-\u00c5ke","family":"L\u00f6\u00f6v","sequence":"additional","affiliation":[{"name":"Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"S\u00f6derling","sequence":"additional","affiliation":[{"name":"Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala, Sweden"},{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Tiihonen","sequence":"additional","affiliation":[{"name":"Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden"},{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland"},{"name":"Neuroscience Center, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Leval","sequence":"additional","affiliation":[{"name":"Janssen-Cilag, Solna, Sweden"},{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gannedahl","sequence":"additional","affiliation":[{"name":"Janssen-Cilag, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Bj\u00f6rkholm","sequence":"additional","affiliation":[{"name":"Janssen-Cilag, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Sj\u00e4lin","sequence":"additional","affiliation":[{"name":"Janssen-Cilag, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Hellner","sequence":"additional","affiliation":[{"name":"Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"},{"name":"Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10159","key":"yoi220078r1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.","volume":"392","author":"James","year":"2018","journal-title":"Lancet"},{"key":"yoi220078r3","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4176825","article-title":"A review of the conceptualisation and risk factors associated with treatment-resistant depression.","volume":"2017","author":"Murphy","year":"2017","journal-title":"Depress Res Treat"},{"issue":"6","key":"yoi220078r4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1177\/0706743719828965","article-title":"Current and common definitions of treatment-resistant depression: findings from a systematic review and qualitative interviews.","volume":"64","author":"Brown","year":"2019","journal-title":"Can J Psychiatry"},{"issue":"8","key":"yoi220078r5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2165\/00023210-200923080-00001","article-title":"STAR*D: revising conventional wisdom.","volume":"23","author":"Rush","year":"2009","journal-title":"CNS Drugs"},{"key":"yoi220078r6","doi-asserted-by":"publisher","DOI":"10.1177\/20451253211006508","article-title":"Excess deaths in treatment-resistant depression.","volume":"11","author":"Brenner","year":"2021","journal-title":"Ther Adv Psychopharmacol"},{"issue":"5","key":"yoi220078r7","first-page":"370","article-title":"Cost burden of treatment resistance in patients with depression.","volume":"16","author":"Gibson","year":"2010","journal-title":"Am J Manag Care"},{"issue":"10","key":"yoi220078r8","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1185\/03007995.2010.517716","article-title":"Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder.","volume":"26","author":"Ivanova","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"yoi220078r9","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jad.2018.06.030","article-title":"Mortality in treatment-resistant unipolar depression: a register-based cohort study in Sweden.","volume":"238","author":"Reutfors","year":"2018","journal-title":"J Affect Disord"},{"issue":"4","key":"yoi220078r10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.31887\/DCNS.2008.10.4\/gipapakostas","article-title":"Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder.","volume":"10","author":"Papakostas","year":"2008","journal-title":"Dialogues Clin Neurosci"},{"issue":"7495","key":"yoi220078r11","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/bmj.330.7495.800","article-title":"Managing depression in primary care.","volume":"330","author":"Tylee","year":"2005","journal-title":"BMJ"},{"issue":"9","key":"yoi220078r12","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/BF02743139","article-title":"Primary care physician office visits for depression by older Americans.","volume":"21","author":"Harman","year":"2006","journal-title":"J Gen Intern Med"},{"issue":"11","key":"yoi220078r13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research.","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"yoi220078r14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1411430","article-title":"The public-private pendulum: patient choice and equity in Sweden.","volume":"372","author":"Anell","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"yoi220078r15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/acps.v146.1","article-title":"Clinical and societal burden of incident major depressive disorder: a population-wide cohort study in Stockholm.","volume":"146","author":"Lundberg","year":"2022","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"yoi220078r17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/bcpt.v125.4","article-title":"Eliminated patient fee and changes in dispensing patterns of asthma medication in children: an interrupted time series analysis.","volume":"125","author":"Dahl\u00e9n","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"7","key":"yoi220078r18","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/da.2018.35.issue-7","article-title":"Finding factors that predict treatment-resistant depression: results of a cohort study.","volume":"35","author":"Cepeda","year":"2018","journal-title":"Depress Anxiety"},{"issue":"1","key":"yoi220078r19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/acps.12959","article-title":"Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study.","volume":"139","author":"Kautzky","year":"2019","journal-title":"Acta Psychiatr Scand"},{"issue":"8","key":"yoi220078r20","doi-asserted-by":"publisher","first-page":"987","DOI":"10.18553\/jmcp.2020.26.8.987","article-title":"Predicting incident treatment-resistant depression: a model designed for health systems of care.","volume":"26","author":"Liberman","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"1-3","key":"yoi220078r21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jad.2011.07.005","article-title":"Agreement between physicians\u2019 and patients\u2019 ratings on the Montgomery-\u00c5sberg Depression Rating Scale.","volume":"135","author":"Cunningham","year":"2011","journal-title":"J Affect Disord"},{"key":"yoi220078r22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jclinepi.2019.02.016","article-title":"The proportion of missing data should not be used to guide decisions on multiple imputation.","volume":"110","author":"Madley-Dowd","year":"2019","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"yoi220078r23","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v045.i04","article-title":"Multiple imputation by chained equations (MICE): implementation in Stata.","volume":"45","author":"Royston","year":"2011","journal-title":"J Stat Softw"},{"issue":"10","key":"yoi220078r24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076882","article-title":"Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database.","volume":"8","author":"Kubitz","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"yoi220078r25","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"key":"yoi220078r26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jad.2021.03.029","article-title":"Treatment patterns in patients with treatment-resistant depression in Danish patients with major depressive disorder.","volume":"287","author":"Gronemann","year":"2021","journal-title":"J Affect Disord"},{"issue":"1","key":"yoi220078r28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1186\/s12888-020-02935-z","article-title":"Investigation of early and lifetime clinical features and comorbidities for the risk of developing treatment-resistant depression in a 13-year nationwide cohort study.","volume":"20","author":"Huang","year":"2020","journal-title":"BMC Psychiatry"},{"issue":"5","key":"yoi220078r29","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/acps.v143.5","article-title":"Low SSRI dosing in clinical practice: a register-based longitudinal study.","volume":"143","author":"Lisinski","year":"2021","journal-title":"Acta Psychiatr Scand"},{"key":"yoi220078r30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jad.2021.03.073","article-title":"Real-world evidence from a European cohort study of patients with treatment resistant depression: treatment patterns and clinical outcomes.","volume":"290","author":"Heerlein","year":"2021","journal-title":"J Affect Disord"},{"issue":"3","key":"yoi220078r31","doi-asserted-by":"publisher","first-page":"344","DOI":"10.4088\/JCP.07m03780","article-title":"Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients.","volume":"70","author":"Szegedi","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"yoi220078r32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12991-019-0248-0","article-title":"All-cause mortality in patients with treatment-resistant depression: a cohort study in the US population.","volume":"18","author":"Li","year":"2019","journal-title":"Ann Gen Psychiatry"},{"issue":"pt A","key":"yoi220078r33","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jad.2020.11.042","article-title":"Cause-specific life years lost in individuals with treatment-resistant depression: a Danish nationwide register-based cohort study.","volume":"280","author":"Madsen","year":"2021","journal-title":"J Affect Disord"},{"issue":"7","key":"yoi220078r34","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1038\/s41380-021-01062-9","article-title":"Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts.","volume":"26","author":"Fabbri","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"2","key":"yoi220078r35","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17m11725","article-title":"Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-cohort study using a US commercial claims database.","volume":"79","author":"Amos","year":"2018","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"yoi220078r36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12888-020-02642-9","article-title":"Risk and risk factors for disability pension among patients with treatment resistant depression: a matched cohort study.","volume":"20","author":"Taipale","year":"2020","journal-title":"BMC Psychiatry"},{"key":"yoi220078r37","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jad.2020.02.023","article-title":"The identification, assessment and management of difficult-to-treat depression: an international consensus statement.","volume":"267","author":"McAllister-Williams","year":"2020","journal-title":"J Affect Disord"},{"issue":"2","key":"yoi220078r38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1176\/appi.ajp.2021.21050535","article-title":"The neglected role of psychotherapy for treatment-resistant depression.","volume":"179","author":"Markowitz","year":"2022","journal-title":"Am J Psychiatry"},{"key":"yoi220078r39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jad.2021.03.019","article-title":"Comparative efficacy and acceptability of neuromodulation procedures in the treatment of treatment-resistant depression: a network meta-analysis of randomized controlled trials.","volume":"287","author":"Li","year":"2021","journal-title":"J Affect Disord"},{"issue":"10","key":"yoi220078r40","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1176\/appi.ajp.2015.14050652","article-title":"Measurement-based care versus standard care for major depression: a randomized controlled trial with blind raters.","volume":"172","author":"Guo","year":"2015","journal-title":"Am J Psychiatry"},{"issue":"12","key":"yoi220078r41","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1038\/sj.npp.1301390","article-title":"Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care.","volume":"32","author":"Trivedi","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"yoi220078r42","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.4088\/JCP.v68n0713","article-title":"Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study.","volume":"68","author":"Souery","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"yoi220078r43","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jad.2013.03.003","article-title":"The societal cost of depression: evidence from 10,000 Swedish patients in psychiatric care.","volume":"150","author":"Ekman","year":"2013","journal-title":"J Affect Disord"},{"issue":"6","key":"yoi220078r44","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.eurpsy.2006.04.005","article-title":"Cost of depression: effect of adherence and treatment response.","volume":"21","author":"von Knorring","year":"2006","journal-title":"Eur Psychiatry"},{"key":"yoi220078r2","first-page":"342","article-title":"Manic-depressive insanity and paranoia.","volume-title":"J Ment Sci","author":"Kraepelin","year":"1921"},{"key":"yoi220078r16","unstructured":"European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Accessed October 20, 2022. https:\/\/www.encepp.eu\/"},{"key":"yoi220078r27","unstructured":"Region Stockholm. Depression [in Swedish]. Accessed September 6, 2022. https:\/\/kunskapsstodforvardgivare.se\/omraden\/psykisk-halsa\/regionala-vardprogram\/depression"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2799488\/jamapsychiatry_lundberg_2022_oi_220078_1675180162.82637.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T11:33:00Z","timestamp":1675251180000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2799488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.3860","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}